Human gliosarcoma-associated ganglioside composition is complex and distinctive as evidenced by high-performance mass spectrometric determination and structural characterization

Glycobiology

Volumn 17, Issue 5, 2007, Pages 504-515

  Vukelić, Željka ^a   Kalanj Bognar, Svjetlana ^a   Froesch, Martin ^b   Bîndilǎ, Laura ^b   Radić, Boris ^c   Allen, Mark ^d   Peter Katalinić, Jasna ^b   Zamfir, Alina D ^e,f  

^a UNIVERSITY OF ZAGREB   (Croatia)

^b UNIVERSITY OF MÜNSTER   (Germany)

^c University of Zagreb School of Medicine   (Croatia)

^d Advion BioSciences Ltd UK   (United Kingdom)

^e VASILE GOLDIS WESTERN UNIVERSITY OF ARAD   (Romania)

^f WEST UNIVERSITY OF TIMISOARA   (Romania)

Author keywords

Biomarkers and target molecules; Ganglioside structures; Gliosarcoma ganglioside composition; High performance mass spectrometry; Novel O acetylated GD3 isomer

Indexed keywords

BIOLOGICAL MARKER; GANGLIOSIDE; GANGLIOSIDE GD 1A; GANGLIOSIDE GD 1B; GANGLIOSIDE GD2; GANGLIOSIDE GM1; GANGLIOSIDE GM1B; GANGLIOSIDE GM2; GANGLIOSIDE GM3; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER CLASSIFICATION; CONTROLLED STUDY; DIAGNOSTIC VALUE; ELECTROSPRAY MASS SPECTROMETRY; GENE SEQUENCE; GLIOSARCOMA; HUMAN; HUMAN TISSUE; ION CYCLOTRON RESONANCE MASS SPECTROMETRY; ISOMERISM; LIPID ANALYSIS; LIPID COMPOSITION; MASS SPECTROMETRY; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE ANALYSIS; SENSITIVITY ANALYSIS; SEQUENCE ANALYSIS; THIN LAYER CHROMATOGRAPHY; TIME OF FLIGHT MASS SPECTROMETRY;

ASTROCYTES; BRAIN CHEMISTRY; BRAIN NEOPLASMS; DIAGNOSIS, DIFFERENTIAL; GANGLIOSIDES; GLIOSARCOMA; HUMANS; MALE; MASS SPECTROMETRY; MIDDLE AGED; OLIGODENDROGLIA; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TUMOR MARKERS, BIOLOGICAL;

EID: 34447324918     PISSN: 09596658     EISSN: 14602423     Source Type: Journal    
DOI: 10.1093/glycob/cwm012     Document Type: Article

References (50)

1. Abad-Rodriguez J, Vallejo-Cremades M, Nieto-Sampedro M. 1998. Control of glial number: Purification from mammalian brain extracts of an inhibitor of astrocyte division. Glia. 23:156-168.
2. Becker R, Rohlfs J, Jennemann R, Wiegandt H, Mennel HD, Bauer BL. 2000. Glycosphingolipid component profiles or human gliomas-correlation to survival time and histopathological malignancy grading. Clin Neuropathol. 19:119-125.
3. Becker R, Eichler MK, Jennemann R, Bertalanffy H. 2002. Phase I clinical trial on adjuvant active immunotherapy of human gliomas with GD2-conjugate. Br J Neurosurg. 16:269-275.
4. Chapman PB. 2003. Vaccinating against GD3 ganglioside using BEC2 antiidiotypic monoclonal antibody. Curr Opin Investig Drugs. 4:710-715.
5. Chen HY, Varki A. 2002. O-acetylation of GD3: An Enigmatic Modification Regulating Apoptosis? J Exp Med. 196:1529-1533.
6. De Laeter JR, Bohlke JK, De Bievre P, Hidaka H, Peiser HS, Rosman KJR, aTaylor PDP. 2003. Atomic weights of the elements: Review 2000 (IUPAC technical report). Pure Appl Chem. 75:683-800.
7. Domon B, Costello CE. 1988. A systematic nomenclature for carbohydrate fragmentations in FAB-MS/MS spectra of glycoconjugates. Glycoconj J. 5:397-409.
8. Fernandez LE, Alonso DF, Gomez DE, Vazquez AM. 2003. Ganglioside-based vaccines and anti-idiotype antibodies for active immunotherapy against cancer. Expert Rev Vaccines. 2:817-823.
9. Fine HA. 2004. J. Toward a glioblastoma vaccine: Promise and potential pitfalls (Editorial). Clin Oncol. 22:1-4.
10. Fredman P, von Holst H, Collins VP, Granholm L, Svennerholm L. 1988. Sialyllactotetraosylceramide, a ganglioside marker for human malignant gliomas. J. Neurochem. 50:912-919.
11. Fredman P. 1994. Gangliosides associated with primary brain tumors and their expression in cell lines established from these tumors. Prog Brain Res. 101: 225-240.
12. Fredman P, Mansson JE, Dellheden B, Bostrom K, von Holst H. 1999. Expression of the GM1-species, [NeuN]-GM1, in a case of human glioma. Neurochem Res. 24:275-279.
13. Fredman P, Hedberg K, Brezicka T. 2003. Gangliosides as therapeutic targets for cancer. BioDrugs. 17:155-167.
14. Froesch M, Bindila L, Baykut G, Allen M, Peter-Katalinic J, Zamfir AD. 2004. Coupling of fully automated chip electrospray to Fourier transform ion cyclotron resonance mass spectrometry for high-performance glycoscreening and sequencing. Rapid Commun Mass Spectrom. 18:3084-3092.
15. Hakomori S. 2001. Tumor-associated carbohydrate antigens defining tumor malignancy: Basis for development of anti-cancer vaccines. Adv Exp Med Biol. 491:369-402.
16. Hakomori S. 2002. Glycosylation defining cancer malignancy: New wine in an old bottle. Proc Natl Acad Sci USA. 99:10231-10233.
17. Hakomori S, Handa K. 2002. Glycosphingolipid-dependent cross-talk between glycosynapses interfacing tumor cells with their host cells: essential basis to define tumor malignancy. FEBS Lett. 531:88-92.
18. Hakomori S. 2004. Glycosynapses: Microdomains controlling carbohydratedependent cell adhesion and signaling. An Acad Bras Cienc. 76:553-572.
19. Hedberg KM, Dellheden B, Wikstrand CJ, Fredman P. 2000. Monoclonal anti-GD3 antibodies selectively inhibit the proliferation of human malignant glioma cells in vitro. Glycoconj J. 17:717-726.
20. Hedberg KM, Mahesparan R, Read TA, Tysnes BB, Thorsen F, Visted T, Bjerkvig R, Fredman P. 2001. The glioma-associated gangliosides 3′-isoLM1, GD3 and GM2 show selective area expression in human glioblastoma xenografts in nude rat brains. Neuropathol Appl Neurobiol. 27: 451-464.
21. IUPAC-IUB Joint Commission on Biochemical Nomenclature (JCNB). Nomenclature of glycolipids. Recommendations 1997. 1998. Eur J Biochem. 257:293-298.
22. Kelly KA, Kirkwood JM, Kapp DS. 1984. Glioblastoma multiforme: pathology, natural history and treatment. Cancer Treat Rev. 11:1-26.
23. Kniep B, Kniep E, Ozkucur N, Barz S, Bachmann M, Malisan F, Testi R, Rieber EP. 2006. 9-O-acetyl GD3 protects tumor cells from apoptosis. Int J Cancer. 119:67-73.
24. Krug LM. 2004. Vaccine therapy for small cell lung cancer. Semin Oncol. 31: 112-116.
25. Luterbach J, Guttenberg R, Pagenstecher A. 2001. Gliosarcoma: A clinical study. Radiother Oncol. 61:57-64.
26. Machuca TN, Prevedello DM, Pope LZ, Haratz SS, Araujo JC, Torres LF. 2004. Gliosarcoma: Report of four cases with immunohistochemical findings. Arq. Neuropsiquiatr. 62:608-612.
27. Malisan F, Testi R. 2002. GD3 ganglioside and apoptosis. Biochim Biophys Acta. 1585:179-187.
28. Mamer OA, Lesimple A. 2004. A common shortcoming in computer programs used to calculate weights in Daltons of ions having elemental compositions entered as input. J. Am Soc Mass Spectrom. 15:626.
29. Metelmann W, Vukelić Ž, Peter-Katalinic ́J. 2001. Nano-ESI quadrupole timeof- flight mass spectrometry of gangliosides from human brain tissue. J. Mass Spectrom. 36:21-29.
30. Miettinen T, Takki-Luukkainen IT. 1959. Use of buthylacetate in determination of sialic acid. Acta Chem Scand. 13:656-658.
31. Mitsuzuka K, Handa K, Satoh M, Arai Y, Hakomori S. 2005. A specific microdomain ("glycosynapse 3") controls phenotypic conversion and reversion of bladder cancer cells through GM3-mediated interaction of alpha3beta1 integrin with CD9. J Biol Chem. 280:35545-35553.
32. Noll EN, Lin J, Nakatsuji Y, Miller RH, Black PM. 2001. GM3 as a novel growth regulator for human gliomas. Exp Neurol. 168:300-309.
33. Ohgaki H, Biernat W, Reis R, Hegi M, Kleihues P. 2000. Gliosarcoma. In: Kleihues P, Cavenee WK, editors. Pathology and Genetic of Tumors of the Nervous System, 2nd ed. Lyon: IARC Press; 42-44.
34. Popko B, Pearl DK, Walker DM, Comas TC, Baerwald KD, Burger PC, Scheithauer BW, Yates AJ. 2002. Molecular markers that identify human astrocytomas and oligodendrogliomas. J Neuropathol Exp Neurol. 61: 329-338.
35. Raffaghello L, Marimpietri D, Pagnan G, Pastorino F, Cosimo E, Brignole C, Ponzoni M, Montaldo PG. 2003. Anti-GD2 monoclonal antibody: A promising strategy in the prevention of neuroblastoma relapse. Cancer Lett. 18: 205-209.
36. Romero-Ramirez L, Nieto-Sampedro M. 2004. Inhibiting human astrocytoma growth: Structure-activity relationships in neurostatin related glycolipids. J Med Chem. 47:4983-4984.
37. Shukla GS, Krag DN. 2006. Selective delivery of therapeutic agents for the diagnosis and treatment of cancer. Expert Opin Biol Ther. 6:39-54.
38. Steiner G, Shaw A, Choo-Smith LP, Abuid MH, Schackert G, Sobottka S, Steller W, Salzer R, Mantsch HH. 2003. Distinguishing and grading human gliomas by IR spectroscopy. Biopolymers. 72:464-471.
39. Svennerholm L. 1957. Quantitative estimation of sialic acids II. A colorimetric resorcinol-hydrochloric acid method. Biochim Biophys Acta. 24:104-111.
40. Svennerholm L. 1963. Chromatographic separation of human brain gangliosides. J Neurochem. 10:613-623.
41. Svennerholm L. 1980. Ganglioside designation. Adv Exp Med Biol. 125, 11.
42. Svennerholm L, Fredman P. 1980. A procedure for the quantitative isolation of brain gangliosides. Biochim Biophys Acta. 617:97-109.
43. Trbojević-Čepe M, Kračun I. 1990. Determination of gangliosides in human cerebrospinal fluid by high-performance thin-layer chromatography and direct densitometry. J Clin Chem Clin Biochem. 8:863-872.
44. Vukelić Ž, Metelmann W, Müthing J, Kos M, Peter-Katalinić J. 2001. Anencephaly: Structural characterization of gangliosides in defined brain regions. Biol Chem. 382:259-274.
45. Vukelić Ž, Zamfir AD, Bindila L, Froesch M, Peter-Katalinić J, Usuki S, Yu RK. 2005. Screening and sequencing of complex sialylated and sulfated glycosphingolipid mixtures by negative ion electrospray Fourier transform ion cyclotron resonance mass spectrometry. J Am Soc Mass Spectrom. 16: 571-580.
46. Varki A, Diaz S. 1984. The release and purification of sialic acids from glycoconjugates: Methods to minimize the loss and migration of O acetyl groups. Anal Biochem. 137:236-247.
47. Wagener R, Rohn G, Schillinger G, Schroder R, Kobbe B, Ernestus RI. 1999. Ganglioside profiles in human gliomas: Quantification by microbore high performance liquid chromatography and correlation to histomorphology and grading. Acta Neurochir (Wien). 141:1339-1345.
48. Zaia J. 2004. Mass spectrometry of oligosaccharides. Mass Spectrom Rev. 23: 161-227.
49. Zamfir A, Vukelić Ž, Bindila L, Peter-Katalinic J, Almeida R, Sterling A, Allen M. 2004. Fully-automated chip-based nanoelectrospray tandem mass spectrometry of gangliosides from human cerebellum. J Am Soc Mass Spectrom. 15:1649-1657.
50. Zamfir AD, Lion N, Vukelić Ž, Bindila L, Rossier J, Girault HH, Peter-Katalinić J. 2005. Thin chip microsprayer system coupled to quadrupole time-of-flight mass spectrometer for glycoconjugate analysis. Lab Chip. 5:298-307.